Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relmada Therapeutics (RLMD) Cash & Equivalents (2016 - 2026)

Relmada Therapeutics has reported Cash & Equivalents over the past 3 years, most recently at $2626.0 for Q1 2014.

  • Quarterly Cash & Equivalents fell 65.01% to $2626.0 in Q1 2014 from the year-ago period, while the trailing twelve-month figure was $2626.0 through Feb 2014, down 65.01% year-over-year, with the annual reading at $15290.0 for FY2013, 70.86% up from the prior year.
  • Cash & Equivalents was $2626.0 for Q1 2014 at Relmada Therapeutics, down from $6166.0 in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $15290.0 in Q3 2013 and troughed at $2626.0 in Q1 2014.
  • The 3-year median for Cash & Equivalents is $8226.5 (2012), against an average of $8496.8.
  • Year-over-year, Cash & Equivalents surged 70.86% in 2013 and then plummeted 65.01% in 2014.
  • A 3-year view of Cash & Equivalents shows it stood at $10446.0 in 2012, then plummeted by 40.97% to $6166.0 in 2013, then tumbled by 57.41% to $2626.0 in 2014.
  • Per Business Quant, the three most recent readings for RLMD's Cash & Equivalents are $2626.0 (Q1 2014), $6166.0 (Q4 2013), and $15290.0 (Q3 2013).